DUBLIN, September 11, 2017 /PRNewswire/ --
The "Global Diabetes Injection Pens Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to Research and Markets' offering.
The global diabetes injection pens market was valued at US$ 5.6 Bn in 2016, and is expected to reach US$ 10.7 Mn by 2025, expanding at a CAGR of 7.2% from 2017 to 2025.
The global diabetes injection pens market is anticipated to progress at a considerable pace over the upcoming years due to increasing diabetes prevalence and corresponding rise in patients in need of regular insulin administration. Introduction of insulin pens and the subsequent smart insulin pens has significantly contributed to rapid proliferation of diabetes injection pens market. Furthermore, growing incidence of needlestick injury corresponding to growing users of insulin injections is additionally driving patients to opt for diabetes injection pens.
The global diabetes injection pens market is segmented based on diabetes type (type I and type II diabetes), product type (insulin pens and insulin pen needles), form (disposable and reusable) and geographical distribution. Among the considered regions, Europe is observed to be a saturated market with moderate movements, where introduction of breakthrough technology may bring an upswing in the market.
United States is the largest revenue generating country-level market with large diabetes prevalence and better awareness and reimbursement for diabetes management. On the other hand, Asia Pacific is observed to be the fastest progressing regional market. Evolving healthcare infrastructure, improving awareness and growing healthcare expenditure majorly drive Asia Pacific diabetes injection pens market.
Some of the notable players in the global diabetes injection pens market are AstraZeneca plc, Becton, Dickinson and Company, Biocon Ltd., Eli Lilly and Company, Jiangsu Delfu Co., Novo Nordisk A/S, Owen Mumford Ltd. and Wockhardt Ltd.
Key Topics Covered:
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
Chapter 2. Executive Summary
2.1. Global Diabetes Injection Pens Market Portraiture
2.1.1. Global Diabetes Injection Pens Market, by Indication, 2016
2.1.2. Global Diabetes Injection Pens Market, by Product Type, 2016
2.1.3. Global Diabetes Injection Pens Market, by Form, 2016
2.1.4. Global Diabetes Injection Pens Market, by Geography, 2016
Chapter 3. Diabetes Injection Pens: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.4.1. Attractive Investment Proposition, by Geography
3.5. Competitive Landscape
3.5.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Diabetes Injection Pens Market, by Indication, 2015 - 2025 (US$ Mn)
4.1. Overview
4.2. Type I Diabetes
4.3. Type II Diabetes
Chapter 5. Global Diabetes Injection Pens Market, by Product Type, 2015 - 2025 (US$ Mn)
5.1. Overview
5.2. Insulin Pens
5.3. Insulin Pen Needles
Chapter 6. Global Diabetes Injection Pens Market, by Form, 2015 - 2025 (US$ Mn)
6.1. Overview
6.2. Disposable
6.3. Reusable
Chapter 7. Global Diabetes Injection Pens Market, by Geography, 2015 - 2025
Chapter 8. Company Profiles
8.1. Astrazeneca Plc
8.1.1. Business Description
8.1.2. Financial Information (Subject to Data Availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Becton, Dickinson and Company
8.3. Biocon Ltd
8.4. Eli Lilly and Company
8.5. Jiangsu Delfu Co
8.6. Novo Nordisk A/S
8.7. Owen Mumford Ltd
8.8. Wockhardt Ltd
8.9. Other Notable Players
For more information about this report visit https://www.researchandmarkets.com/research/8sv3pf/global_diabetes
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
